ARCHIVES

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

This article is from The Cancer Letter archive.

Vol. 37 No. 46 | December 16, 2011

Download PDF Visit The Full Archive

Related Articles

Study Examines Lung Cancer Among Lifelong Nonsmokers

October 31, 2008

Hatch Hearing Turns Up Few New Deficiencies In NCI Contract Management; DeVita Blasted On Strauss

June 5, 1981

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

September 26, 2014

Arzerra Given Accelerated Approval For Leukemia

October 30, 2009

Women Are Less Active After A Diagnosis of Breast Cancer

March 28, 2003

NCAB Working Group To Hold Open And Closed Sessions

January 20, 1995